周二,Cantor Fitzgerald重申了对Avita Medical Ltd.(纳斯达克股票代码:RCEL)的增持评级和21.00美元的目标价,这意味着相对于当前11.75美元的价格有近80%的上涨空间。根据InvestingPro数据,分析师的目标价范围从11.38美元到20.94美元不等,该股票在过去一年中显示出显著的价格波动。
HEFEI, Dec 26 (China Economic Net) - The International Molecular Pathology Training Program hosted by the Ministry of Science and Technology of China concluded at Anhui Medical University on Dec 24.
The latest bulk procurement included some 11,000 cochlear implants purchased from five suppliers, as well as 258,000 peripheral vascular stents obtained from 18 suppliers, the National Healthcare ...